We have developed a VASH1 enzyme‐linked immunosorbent assay (ELISA) that can detect the 44‐ and 36‐kDa VASH1 forms that preserve antiangiogenic activity.11, 22 Here, we applied this system, determined the preoperative plasma VASH1 concentration in patients with lung cancer, and evaluated its potential value as a prognostic factor in patients after surgery. Here, VASH1 is linked to lung carcinoma.